USPTO serial 74593428
"HIT"
Reviewed by CopyMark Law Group
Reg. 2108093Status 710
- Filing date
- Status date
- Registration date
- Oct 28, 1997
- Examiner
- MANDIR, FREDERICK
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with "HIT"?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
HYAL PHARMACEUTICAL CORPORATION
Toronto, Ontario, CA
HYAL PHARMACEUTICAL CORPORATION
Toronto, Ontario, CA
HYAL PHARMACEUTICAL CORPORATION
Toronto, Ontario, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
IVOR M. HUGHES
IVOR M HUGHES HUGHES, ETIGSON175 COMMERCE VALLEY DR WSTE 200THORNHILL, ON L3T 7P6Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceutical preparations comprising hyaluronan, adapted for the topical, injectable, and intravenous treatment of the following - cancer, increasing activity of macrophages; reduction of swelling in the brain of person suffering brain trauma; herpes, canker sore, shingles; renal failure, cardiac insufficiency, hypertension, edema; infection, acne, monoucleosis; transplants; inflammation, elimination of tumor breakdown material (toxins and debris), decreasing side effects, relief of pain; detoxification; bronchodilation; vascular ischemia; HIV (AIDS); diabetes; post-menopause; prevention of topical infection; reduction of swelling; hypertension, cardiac insufficiency; prostaglandin synthesis inhibition; enhancement of oxygenation of tissue by perfusion fluid bathing of the tissue (for transplantation purposes); sub-retinal neovascularization and as an adjunct to the treatment of cancer to prevent metastasis; arthitis or pannus; cancer tumours; inhibiting angiogenesis; controlling angiogenesis; regressing angiogenesis; basal cell carcinoma; actinic keratoses; liver spots; squamous cell tumours; metastatic cancer of the breast to the skin; primary and metastatic melanoma of the skin; malignancies and/or tumour of the skin; genital warts (condyloma acuminata); cervical cancer; Human Papilloma Virus (HPV); psoriasis, corns on the feet; and hair loss on the heads of pregnant women; topical treatment of pain in the skin and or exposed tissue; clearing of atherosclerosis; prevention of arterial restenosis after balloon angioplasty; macrophage infilitration | SECTION 8 - CANCELLED | — |
| 042 | licensing the intellectual property technology regarding pharmaceutical preparations comprising hyaluronan, adapted for the topical, injectable, and intravenous treatment of medical conditions and disease in humans | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by HYAL PHARMACEUTICAL CORPORATION
- Other trademarks owned by HYAL PHARMACEUTICAL CORPORATION
- Other trademarks owned by HYAL PHARMACEUTICAL CORPORATION
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named "HIT"
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 31, 2004 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Oct 28, 1997 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 5, 1997 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 4, 1997 | NPUB | NOTICE OF PUBLICATION | — |
| May 19, 1997 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 2, 1997 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 8, 1997 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 3, 1996 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 6, 1996 | UNPR | UNRESPONSIVE/DUPLICATE PAPER RECEIVED | — |
| Jun 4, 1996 | CNSI | INQUIRY AS TO SUSPENSION MAILED | — |
| Jan 6, 1996 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Oct 6, 1995 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 8, 1995 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 17, 1995 | DOCK | ASSIGNED TO EXAMINER | — |